EIKN
Eikon Therapeutics, Inc. Common StockHealthcare·Biotechnology
$10.84
$32M market cap
Revenue
$0.0M
Free Cash Flow
$-131.8M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of protein interactions in living cells. Its products includes EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004 are selective PARP1 inhibitors in ovarian, breast, prost
2-Year Price History
$10.91-24.8%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -82.2 | -87.3 | -83.0 | -89.8 | -90.1 | -0.3 | 512.6 | 254.8 | 54.1 | -20.7% | -- | -- |
| Act | 2025-Q4 | 0.0 | -78.1 | -83.2 | -79.7 | -41.7 | -41.8 | -0.1 | 336.0 | 257.3 | 54.1 | -129.3% | -- | -- |
Valuation & Metrics
Market Stats
Price$10.84
Market Cap$32M
Enterprise Value$-226M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-412.2%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-162.6M
Free Cash Flow$-131.8M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-75.0%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares3.4M
Days to Cover18.7
Change (vs Prior)-4.9%
Need at least 2 settlement dates for chart
Employees
Headcount484
Revenue / Employee$0
Gross Profit / Employee$-21,112
Cash Runway
46.6months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
592.8%
42 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
152.7%
8 filers
Vanguard, iShares, SPDR
Market makers
8.5%
2 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
Not enough quarterly ownership history to chart yet.
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| FMR LLC | $40.6M | $10.58 | +$40.6M | +$40.6M | — | $1.89T |
| BlackRock, Inc.Passive | $35.1M | $10.58 | +$35.1M | +$35.1M | — | $5.69T |
| Foresite Capital Management IV, LLC | $20.6M | $10.58 | +$20.6M | +$20.6M | — | $237M |
| Merck & Co., Inc. | $17.6M | $10.58 | +$17.6M | +$17.6M | — | $349M |
| Foresite Capital Management V, LLC | $14.0M | $10.58 | +$14.0M | +$14.0M | — | $271M |
| T. Rowe Price Investment Management, Inc. | $12.9M | $10.58 | +$12.9M | +$12.9M | — | $145.22B |
| Capital World Investors | $12.1M | $10.58 | +$12.1M | +$12.1M | — | $732.46B |
| ALLIANCEBERNSTEIN L.P. | $10.8M | $10.58 | +$10.8M | +$10.8M | — | $307.70B |
| PRICE T ROWE ASSOCIATES INC /MD/ | $10.3M | $10.58 | +$10.3M | +$10.3M | — | $864.93B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $10.3M | $10.58 | +$10.3M | +$10.3M | — | $4.04T |
| EcoR1 Capital, LLC | $7.8M | $10.58 | +$7.8M | +$7.8M | — | $2.34B |
| BAKER BROS. ADVISORS LP | $5.9M | $10.58 | +$5.9M | +$5.9M | — | $16.13B |
| SOROS CAPITAL MANAGEMENT LLC | $5.1M | $10.58 | +$5.1M | +$5.1M | — | $230M |
| StepStone Group LP | $4.2M | $10.58 | +$4.2M | +$4.2M | — | $207M |
| CANADA PENSION PLAN INVESTMENT BOARD | $4.0M | $10.58 | +$4.0M | +$4.0M | — | $155.02B |
| FRANKLIN RESOURCES INC | $3.7M | $10.58 | +$3.7M | +$3.7M | — | $403.03B |
| CITADEL ADVISORS LLC | $3.3M | $10.58 | +$3.3M | +$3.3M | — | $138.22B |
| General Catalyst Group Management, LLC | $3.2M | $10.58 | +$3.2M | +$3.2M | — | $184M |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $2.9M | $10.58 | +$2.9M | +$2.9M | — | $1.61T |
| JANE STREET GROUP, LLCMM | $2.8M | $10.58 | +$2.8M | +$2.8M | — | $92.10B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-0.78%
avg per quarter
Holders (ex-self)
—
excl. this stock
Buyers (this Q)
-0.78%
52 buyers · $0.25B in
Sellers (this Q)
+0.00%
0 sellers · $0.00B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
-5.4%
how holders react when this stock falls
On quiet Qs
-2.4%
−10% to +10% baseline
On rallies (+10%+)
-3.5%
how they react when this stock rises
Holders' portfolio flow this Q
+2.9%
inflows — adds are organic
Sellers' portfolio flow this Q
+0.0%
Sellers' overall flow ~ flat.
New buyers this quarter
FMR LLC+$0.04BBlackRock, Inc.+$0.04BForesite Capital Management IV, LLC+$0.02BMerck & Co., Inc.+$0.02BForesite Capital Management V, LLC+$0.01BT. Rowe Price Investment Management, Inc.+$0.01BCapital World Investors+$0.01BALLIANCEBERNSTEIN L.P.+$0.01BPRICE T ROWE ASSOCIATES INC /MD/+$0.01BVANGUARD CAPITAL MANAGEMENT LLC+$0.01B
Top-5 holders · 50.9%
FMR LLC--
BlackRock, Inc.--
Foresite Capital Management IV, LLC--
Merck & Co., Inc.--
Foresite Capital Management V, LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
Not enough holder history to plot.
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | 3 | 160.64× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$5.00-5390.0%
Last Year (1 analysts)$5.00-5390.0%
Current Price$10.84
Analyst Ratings
1
Sell: 1Consensus: Sell
Corporate
Order Flow (FINRA, ~3w lag)
18.0%retail+2.1pp
33.8%dark+3.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.